DOCSLIB.ORG

COVID-19 Publications - Week 22 2020 709 Publications

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Update May 25 - May 31, 2020, Dr. Peter J. Lansberg MD, PhD Weekly COVID-19 Literature Update will keep you up-to-date with all recent PubMed publications categorized by relevant topics COVID-19 publications - Week 22 2020 709 Publications PubMed based Covid-19 weekly literature update For those interested in receiving weekly updates click here For questions and requests for topics to add send an e-mail [email protected] Reliable on-line resources for Covid 19 WHO Cochrane Daily dashbord BMJ Country Guidance The Lancet Travel restriction New England Journal of Medicine Covid Counter JAMA Covid forcasts Cell CDC Science AHA Oxford Universtiy Press ESC Cambridge Univeristy Press EMEA Springer Nature Evidence EPPI Elsevier Wikipedia Wiley Cardionerds - COVID-19 PLOS Genomic epidemiology LitCovid NIH-NLM Oxygenation Ventilation toolkit SSRN (Pre-prints) German (ICU) bed capacity COVID reference (Steinhauser Verlag) COVID-19 Projections tracker AAN - Neurology resources COVID-19 resources (Harvard) COVID-19 resources (McMasters) COVID-19 resources (NHLBI) COVID-19 resources (MEDSCAPE) COVID-19 Diabetes (JDRF) COVID-19 TELEMEDICINE (BMJ) Global Causes of death (Johns Hopkins) Guidelines NICE Guidelines Covid-19 Korean CDC Covid-19 guidelines Flattening the curve - Korea IDSA COVID-19 Guidelines Airway Management Clinical Practice Guidelines (SIAARTI/EAMS, 2020) ESICM Ventilation Guidelines Performing Procedures on Patients With Known or Suspected COVID-19 (ASA, 2020) OSHA Guidance on Preparing the Workplace for COVID-19 (2020) Policy for Sterilizers, Disinfectant Devices, and Air Purifiers (FDA, 2020) Breast Cancer Patient Triage Guidelines (CPBCC, 2020) clinical guidance for adult Belgian patients with suspected or confirmed COVID-19 National Covid-19 Testing Action Plan (Rockefeller Foundation) ASE issues Echo-cardiography guidance Trials & Registries CAPACITY European registry COVID 19 patients WHO launches global megatrial FDA launches Convalescent plasma trial Lets Beat Covid-19 Survey to help plan hospital services COVID IBD registry Google mobility reports per country COVID 19 World's largest trial of potential coronavirus treatments rolled out across the UK Pregnancy Registry (US) ICNARC report on COVID-19 in critical care - NHS April 24 COVID-19 Human Genetics - Biobanks COVID19 settings of transmission database Mainstream Media U.S. plans massive coronavirus vaccine testing to meet year-end deadline (Reuters) Japan's 3 Cs”—closed spaces, crowds, and close-contact settings (Science) Alzheimer’s Gene (E2/E2) Linked to Higher Risk of Severe COVID-19 (Scientist) COVID-19 Vaccine Researchers Mindful of Immune Enhancement (Scientist) Hydroxychloroquine study questioned by 120 researchers (Guardian) The World Is Still Far From Herd Immunity for Coronavirus (NYT) What’s the Risk of Catching Coronavirus From a Surface? (NYT) Masks helped keep Japan's COVID-19 death toll low, says expert panel There will probably be a second wave (Guardian) Death threats after a trial on chloroquine for COVID-19 (Lancet) genomics to help avoid a second coronavirus wave (Nature) Ethical guidelines for COVID-19 tracing apps (Nature) It’s Not Whether You Were Exposed to the Virus. It’s How Much (NYT) Disputed Hydroxychloroquine Study Brings Scrutiny to Surgisphere (Scientist) Researchers Applaud Spanish COVID-19 Serological Survey (Scientist) Genetic risk factors for Alzheimer’s also raise the risk of getting COVID-19 (Science) How to Improve and Protect Nursing Homes From Outbreaks (NYT) Karl Friston: 'Germany may have more immunological “dark matter” (Guardian) KeyArticles 1. Challenges in Laboratory Diagnosis of the Novel Coronavirus SARS- CoV-2. Viruses 2020; 12Younes N, Al-Sadeq DW, Al-Jighefee H et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=32466458 2. Early risk factors of the exacerbation of Coronavirus disease 2019 pneumonia. J Med Virol 2020; Wang CZ, Hu SL, Wang L et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=32470167 3. The Spectrum of Cardiac Manifestations in Coronavirus Disease 2019 (COVID-19) - a Systematic Echocardiographic Study. Circulation 2020; Szekely Y, Lichter Y, Taieb P et al. http://www.ncbi.nlm.nih.gov/pubmed/? term=32469253 4. Early Outpatient Treatment of Symptomatic, High-Risk Covid-19 Patients that Should be Ramped-Up Immediately as Key to the Pandemic Crisis. Am. J. Epidemiol. 2020; Risch HA. http://www.ncbi.nlm.nih.gov/pubmed/? term=32458969 5. Experience with Hydroxychloroquine and Azithromycin in the COVID-19 Pandemic: Implications for QT Interval Monitoring. J Am Heart Assoc 2020:e017144Ramireddy A, Chugh H, Reinier K et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=32463348 6. COVID-19 and NSAIDS: A Narrative Review of Knowns and Unknowns. Pain Ther 2020; Pergolizzi JV, Jr., Varrassi G, Magnusson P et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=32447629 7. The mechanistic overview of SARS-CoV-2 using angiotensin-converting enzyme 2 to enter the cell for replication: possible treatment options related to the renin-angiotensin system. Eur Heart J Cardiovasc Pharmacother 2020; Offringa A, Montijn R, Singh S et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=32464637 8. Potential Benefits and Harms of Novel Antidiabetic Drugs During COVID- 19 Crisis. Int J Environ Res Public Health 2020; 17Mirabelli M, Chiefari E, Puccio L et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=32456064 9. Cardiovascular disease potentially contributes to the progression and poor prognosis of COVID-19. Nutr. Metab. Cardiovasc. Dis. 2020; Li M, Dong Y, Wang H et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=32456948 10. Obesity and COVID-19: Immune and metabolic derangement as a possible link to adverse clinical outcomes. Am J Physiol Endocrinol Metab 2020; Korakas E, Ikonomidis I, Kousathana F et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=32459524 11. Predictors for Severe COVID-19 Infection. Clin Infect Dis 2020; Bhargava A, Fukushima EA, Levine M et al. http://www.ncbi.nlm.nih.gov/pubmed/? term=32472676 12. Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors. J. Thromb. Thrombolysis 2020; Artifoni M, Danic G, Gautier G et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=32451823 Basic Science (23 articles) 1. Metformin and SARS-CoV-2: mechanistic lessons on air pollution to weather the cytokine/thrombotic storm in COVID-19. Aging (Albany NY) 2020; 12Menendez JA. http://www.ncbi.nlm.nih.gov/pubmed/?term=32463794 2. A possible strategy to fight COVID-19: Interfering with spike glycoprotein trimerization. Biochem. Biophys. Res. Commun. 2020; Bongini P, Trezza A, Bianchini M et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=32451080 3. Stability of RNA sequences derived from the coronavirus genome in human cells. Biochem. Biophys. Res. Commun. 2020; Wakida H, Kawata K, Yamaji Y et al. http://www.ncbi.nlm.nih.gov/pubmed/? term=32446559 4. Tripartite Combination of Candidate Pandemic Mitigation Agents: Vitamin D, Quercetin, and Estradiol Manifest Properties of Medicinal Agents for Targeted Mitigation of the COVID-19 Pandemic Defined by Genomics-Guided Tracing of SARS-CoV-2 Targets in Human Cells. Biomedicines 2020; 8Glinsky GV. http://www.ncbi.nlm.nih.gov/pubmed/?term=32455629 5. Animal models of mechanisms of SARS-CoV-2 infection and COVID-19 pathology. Br. J. Pharmacol. 2020; Cleary SJ, Pitchford SC, Amison RT et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=32462701 6. Metatranscriptomic Characterization of COVID-19 Identified A Host Transcriptional Classifier Associated With Immune Signaling. Clin Infect Dis 2020; Zhang H, Ai JW, Yang W et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=32463434 7. Physicochemical properties of SARS-CoV-2 for drug targeting, virus inactivation and attenuation, vaccine formulation and quality control. Electrophoresis 2020; Scheller C, Krebs F, Minkner R et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=32469436 8. SARS-CoV-2 Phylogenetic Analysis, Lazio Region, Italy, February-March 2020. Emerg Infect Dis 2020; 26Bartolini B, Rueca M, Gruber CEM et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=32459984 9. Type I astrocytes and microglia induce a cytokine response in an encephalitic murine coronavirus infection. Exp. Mol. Pathol. 2020:104474Lavi E, Cong L. http://www.ncbi.nlm.nih.gov/pubmed/? term=32454103 10. High throughput virtual screening reveals SARS-CoV-2 multi-target binding natural compounds to lead instant therapy for COVID-19 treatment. Int. J. Biol. Macromol. 2020; Naik B, Gupta N, Ojha R et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=32470577 11. ACE2, TMPRSS2 AND FURIN GENE EXPRESSION IN THE AIRWAYS OF PEOPLE WITH ASTHMA - IMPLICATIONS FOR COVID-19. J Allergy Clin Immunol 2020; Bradding P, Richardson M, Hinks TSC et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=32450087 12. Molecular Docking, Simulation and MM-PBSA Studies of Nigella Sativa Compounds: A Computational Quest to identify Potential Natural Antiviral for COVID-19 Treatment. J Biomol Struct Dyn 2020:1-16Ahmad S, Abbasi HW, Shahid S et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=32462996 13. Docking study of Chloroquine and Hydroxychloroquine interaction with SARS-CoV-2 spike glycoprotein-An in silico insight into the comparative efficacy of repurposing antiviral drugs. J Biomol Struct Dyn 2020:1-11Amin M, Abbas G. http://www.ncbi.nlm.nih.gov/pubmed/?term=32469265 14. Fragment tailoring strategy to design novel chemical entities as potential binders of novel corona virus main protease. J Biomol Struct Dyn 2020:1-15Choudhury C. http://www.ncbi.nlm.nih.gov/pubmed/? term=32452282 15. Withanone and withaferin-A are predicted to interact with transmembrane protease serine 2 (TMPRSS2) and block entry of SARS-CoV-2 into cells. J Biomol Struct Dyn 2020:1-27Kumar V, Dhanjal JK, Bhargava P et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=32469279 16. Early Phylogenetic Diversification of SARS-CoV-2: Determination of Variants and the Effect on Epidemiology, Immunology, and Diagnostics. J Clin Med 2020; 9Kaden R.
Recommended publications
  • COVID-19 Publications - Week 05 2021 1328 Publications

    COVID-19 Publications - Week 05 2021 1328 Publications

    Update February 1 - February 7, 2021, Dr. Peter J. Lansberg MD, PhD Weekly COVID-19 Literature Update will keep you up-to-date with all recent PubMed publications categorized by relevant topics COVID-19 publications - Week 05 2021 1328 Publications PubMed based Covid-19 weekly literature update For those interested in receiving weekly updates click here For questions and requests for topics to add send an e-mail [email protected] Reliable on-line resources for Covid 19 WHO Cochrane Daily dashbord BMJ Country Guidance The Lancet Travel restriction New England Journal of Medicine Covid Counter JAMA Covid forcasts Cell CDC Science AHA Oxford Universtiy Press ESC Cambridge Univeristy Press EMEA Springer Nature Evidence EPPI Elsevier Wikipedia Wiley Cardionerds - COVID-19 PLOS Genomic epidemiology LitCovid NIH-NLM Oxygenation Ventilation toolkit SSRN (Pre-prints) German (ICU) bed capacity COVID reference (Steinhauser Verlag) COVID-19 Projections tracker Retracted papers AAN - Neurology resources COVID-19 risk tools - Apps COVID-19 resources (Harvard) Web app for SARS-CoV2 mutations COVID-19 resources (McMasters) COVID-19 resources (NHLBI) COVID-19 resources (MEDSCAPE) COVID-19 Diabetes (JDRF) COVID-19 TELEMEDICINE (BMJ) Global Causes of death (Johns Hopkins) COVID-19 calculators (Medscap) Guidelines NICE Guidelines Covid-19 Korean CDC Covid-19 guidelines Flattening the curve - Korea IDSA COVID-19 Guidelines Airway Management Clinical Practice Guidelines (SIAARTI/EAMS, 2020) ESICM Ventilation Guidelines Performing Procedures on Patients With
  • Estimating the Serial Interval of the Novel Coronavirus Disease (COVID

    Estimating the Serial Interval of the Novel Coronavirus Disease (COVID

    medRxiv preprint doi: https://doi.org/10.1101/2020.02.21.20026559; this version posted February 25, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . 1 Estimating the serial interval of the novel coronavirus disease 2 (COVID-19): A statistical analysis using the public data in Hong Kong 3 from January 16 to February 15, 2020 4 Shi Zhao1,2,*, Daozhou Gao3, Zian Zhuang4, Marc KC Chong1,2, Yongli Cai5, Jinjun Ran6, Peihua Cao7, Kai 5 Wang8, Yijun Lou4, Weiming Wang5,*, Lin Yang9, Daihai He4,*, and Maggie H Wang1,2 6 7 1 JC School of Public Health and Primary Care, Chinese University of Hong Kong, Hong Kong, China 8 2 Shenzhen Research Institute of Chinese University of Hong Kong, Shenzhen, China 9 3 Department of Mathematics, Shanghai Normal University, Shanghai, China 10 4 Department of Applied Mathematics, Hong Kong Polytechnic University, Hong Kong, China 11 5 School of Mathematics and Statistics, Huaiyin Normal University, Huaian, China 12 6 School of Public Health, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, China 13 7 Clinical Research Centre, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China 14 8 Department of Medical Engineering and Technology, Xinjiang Medical University, Urumqi, 830011, China 15 9 School of Nursing, Hong Kong Polytechnic University, Hong Kong, China 16 * Correspondence
  • Design and Characterization of Inulin Conjugate for Improved Intracellular and Targeted Delivery of Pyrazinoic Acid to Monocytes

    Design and Characterization of Inulin Conjugate for Improved Intracellular and Targeted Delivery of Pyrazinoic Acid to Monocytes

    pharmaceutics Article Design and Characterization of Inulin Conjugate for Improved Intracellular and Targeted Delivery of Pyrazinoic Acid to Monocytes Franklin Afinjuomo 1, Thomas G. Barclay 1, Ankit Parikh 1, Yunmei Song 1, Rosa Chung 1, Lixin Wang 1, Liang Liu 1, John D. Hayball 1, Nikolai Petrovsky 2,3 and Sanjay Garg 1,* 1 School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, SA 5001, Australia; olumide.afi[email protected] (F.A.); [email protected] (T.G.B.); [email protected] (A.P.); [email protected] (Y.S.); [email protected] (R.C.); [email protected] (L.W.); [email protected] (L.L.); [email protected] (J.D.H.) 2 Vaxine Pty. Ltd., Adelaide, SA 5042, Australia; nikolai.petrovsky@flinders.edu.au 3 Department of Endocrinology, Flinders University, Adelaide, SA 5042, Australia * Correspondence: [email protected]; Tel.: +61-8-8302-1567 Received: 26 April 2019; Accepted: 16 May 2019; Published: 22 May 2019 Abstract: The propensity of monocytes to migrate into sites of mycobacterium tuberculosis (TB) infection and then become infected themselves makes them potential targets for delivery of drugs intracellularly to the tubercle bacilli reservoir. Conventional TB drugs are less effective because of poor intracellular delivery to this bacterial sanctuary. This study highlights the potential of using semicrystalline delta inulin particles that are readily internalised by monocytes for a monocyte-based drug delivery system. Pyrazinoic acid was successfully attached covalently to the delta inulin particles via a labile linker.
  • The Serial Interval of COVID-19 from Publicly Reported Confirmed Cases

    The Serial Interval of COVID-19 from Publicly Reported Confirmed Cases

    medRxiv preprint doi: https://doi.org/10.1101/2020.02.19.20025452; this version posted March 13, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Title: The serial interval of COVID-19 from publicly reported confirmed cases Running Head: The serial interval of COVID-19 1,+ 2+ 3,4+ 5, 6 Authors: Zhanwei Du ,​ Xiaoke Xu ,​ Ye Wu ,​ Lin Wang ,​ Benjamin J. Cowling ,​ and ​ ​ ​ ​ ​ ​ Lauren Ancel Meyers1,7* ​ Affiliations: 1. The University of Texas at Austin, Austin, Texas 78712, The United States of America 2. Dalian Minzu University, Dalian 116600, China 3. Computational Communication Research Center, Beijing Normal University, Zhuhai, 519087, China 4. School of Journalism and Communication, Beijing Normal University, Beijing, 100875, China 5. Institut Pasteur, 28 rue du Dr Roux, Paris 75015, France 6. The University of Hong Kong, Hong Kong SAR, China 7. Santa Fe Institute, Santa Fe, New Mexico, The United States of America Corresponding author: Lauren Ancel Meyers Corresponding author email: [email protected] + ​ These first authors contributed equally to this article Short Abstract (50 words) We estimate the distribution of serial intervals for 468 confirmed cases of COVID-19 reported in 93 Chinese cities by February 8, 2020. The mean and standard deviation are 3.96 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
  • Advances in Nanomaterials in Biomedicine

    Advances in Nanomaterials in Biomedicine

    nanomaterials Editorial Advances in Nanomaterials in Biomedicine Elena Ryabchikova Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of Russian Academy of Science, 8 Lavrentiev Ave., 630090 Novosibirsk, Russia; [email protected] Keywords: nanotechnology; nanomedicine; biocompatible nanomaterials; diagnostics; nanocarriers; targeted drug delivery; tissue engineering Biomedicine is actively developing a methodological network that brings together biological research and its medical applications. Biomedicine, in fact, is at the front flank of the creation of the latest technologies for various fields in medicine, and, obviously, nanotechnologies occupy an important place at this flank. Based on the well-known breadth of the concept of “Biomedicine”, the boundaries of the Special Issue “Advances in Nanomaterials in Biomedicine” were not limited, and authors could present their work from various fields of nanotechnology, as well as new methods and nanomaterials intended for medical applications. This approach made it possible to make public not only specific developments, but also served as a kind of mirror reflecting the most active interest of researchers in a particular field of application of nanotechnology in biomedicine. The Special Issue brought together more than 110 authors from different countries, who submitted 11 original research articles and 7 reviews, and conveyed their vision of the problems of nanomaterials in biomedicine to the readers. A detailed and well-illustrated review on the main problems of nanomedicine in onco-immunotherapy was presented by Acebes-Fernández and co-authors [1]. It should be noted that the review is not limited to onco-immunotherapy, and gives a complete understanding of nanomedicine in general, which is useful for those new to this field.
  • Using Proper Mean Generation Intervals in Modeling of COVID-19

    Using Proper Mean Generation Intervals in Modeling of COVID-19

    ORIGINAL RESEARCH published: 05 July 2021 doi: 10.3389/fpubh.2021.691262 Using Proper Mean Generation Intervals in Modeling of COVID-19 Xiujuan Tang 1, Salihu S. Musa 2,3, Shi Zhao 4,5, Shujiang Mei 1 and Daihai He 2* 1 Shenzhen Center for Disease Control and Prevention, Shenzhen, China, 2 Department of Applied Mathematics, The Hong Kong Polytechnic University, Hong Kong, China, 3 Department of Mathematics, Kano University of Science and Technology, Wudil, Nigeria, 4 The Jockey Club School of Public Health and Primary Care, Chinese University of Hong Kong, Hong Kong, China, 5 Shenzhen Research Institute of Chinese University of Hong Kong, Shenzhen, China In susceptible–exposed–infectious–recovered (SEIR) epidemic models, with the exponentially distributed duration of exposed/infectious statuses, the mean generation interval (GI, time lag between infections of a primary case and its secondary case) equals the mean latent period (LP) plus the mean infectious period (IP). It was widely reported that the GI for COVID-19 is as short as 5 days. However, many works in top journals used longer LP or IP with the sum (i.e., GI), e.g., >7 days. This discrepancy will lead to overestimated basic reproductive number and exaggerated expectation of Edited by: infection attack rate (AR) and control efficacy. We argue that it is important to use Reza Lashgari, suitable epidemiological parameter values for proper estimation/prediction. Furthermore, Institute for Research in Fundamental we propose an epidemic model to assess the transmission dynamics of COVID-19 Sciences, Iran for Belgium, Israel, and the United Arab Emirates (UAE).
  • Serial Interval of COVID-19 Among Publicly Reported Confirmed Cases

    Serial Interval of COVID-19 Among Publicly Reported Confirmed Cases

    RESEARCH LETTERS of an outbreak of 2019 novel coronavirus diseases and the extent of interventions required to control (COVID-19)—China, 2020. China CDC Weekly 2020 [cited an epidemic (3). 2020 Feb 29]. http://weekly.chinacdc.cn/en/article/id/ e53946e2-c6c4-41e9-9a9b-fea8db1a8f51 To obtain reliable estimates of the serial interval, we obtained data on 468 COVID-19 transmission events Address for correspondence: Nick Wilson, Department of reported in mainland China outside of Hubei Province Public Health, University of Otago Wellington, Mein St, during January 21–February 8, 2020. Each report con- Newtown, Wellington 6005, New Zealand; email: sists of a probable date of symptom onset for both the [email protected] infector and infectee, as well as the probable locations of infection for both case-patients. The data include only confirmed cases compiled from online reports from 18 provincial centers for disease control and prevention (https://github.com/MeyersLabUTexas/COVID-19). Fifty-nine of the 468 reports indicate that the in- fectee had symptoms earlier than the infector. Thus, presymptomatic transmission might be occurring. Given these negative-valued serial intervals, COV- ID-19 serial intervals seem to resemble a normal distri- bution more than the commonly assumed gamma or Serial Interval of COVID-19 Weibull distributions (4,5), which are limited to posi- among Publicly Reported tive values (Appendix, https://wwwnc.cdc.gov/EID/ Confirmed Cases article/26/7/20-0357-App1.pdf). We estimate a mean serial interval for COVID-19 of 3.96 (95% CI 3.53–4.39) days, with an SD of 4.75 (95% CI 4.46–5.07) days (Fig- Zhanwei Du,1 Xiaoke Xu,1 Ye Wu,1 Lin Wang, ure), which is considerably lower than reported mean Benjamin J.
  • Introducing Bionanotechnology Into Undergraduate Biomedical Engineering

    Introducing Bionanotechnology Into Undergraduate Biomedical Engineering

    AC 2009-504: INTRODUCING BIONANOTECHNOLOGY INTO UNDERGRADUATE BIOMEDICAL ENGINEERING Aura Gimm, Duke University J. Aura Gimm is Assistant Professor of the Practice and Associated Director of Undergraduate Studies in the Department of Biomedical Engineering at Duke University. She teaches courses in biomaterials, thermodynamics/kinetics, engineering design, and a new course in bionanotechnology. Dr. Gimm received her S.B. in Chemical Engineering and Biology from MIT, and her Ph.D. in Bioengineering from UC-Berkeley. Page 14.802.1 Page © American Society for Engineering Education, 2009 Introducing Bionanotechnology in Undergraduate Biomedical Engineering Abstract As a part of the NSF-funded Nanotechnology Undergraduate Education Program, we have developed and implemented a new upper division elective course in Biomedical Engineering titled “Introduction to Bionanotechnology Engineering”. The pilot course included five hands- on “Nanolab” modules that guided students through specific aspects of nanomaterials and engineering design in addition to lecture topics such as scaling effects, quantum effects, electrical/optical properties at nanoscale, self-assembly, nanostructures, nanofabrication, biomotors, biological designing, biosensors, etc. Students also interacted with researchers currently working in the areas of nanomedicine, self-assembly, tribiology, and nanobiomaterials to learn first-hand the engineering and design challenges. The course culminated with research or design proposals and oral presentations that addressed specific engineering/design issues facing nanobiotechnology and/or nanomedicine. The assessment also included an exam (only first offering), laboratory write-ups, reading of research journal articles and analysis, and an essay on ethical/societal implications of nanotechnology, and summative questionnaire. The course exposed students to cross-disciplinary intersections that occur between biomedical engineering, materials science, chemistry, physics, and biology when working at the nanoscale.
  • Nanotechnology in Regenerative Medicine: the Materials Side

    Nanotechnology in Regenerative Medicine: the Materials Side

    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by UPCommons. Portal del coneixement obert de la UPC Review Nanotechnology in regenerative medicine: the materials side Elisabeth Engel, Alexandra Michiardi, Melba Navarro, Damien Lacroix and Josep A. Planell Institute for Bioengineering of Catalonia (IBEC), Department of Materials Science, Technical University of Catalonia, CIBER BBN, Barcelona, Spain Regenerative medicine is an emerging multidisciplinary structures and materials with nanoscale features that can field that aims to restore, maintain or enhance tissues mimic the natural environment of cells, to promote certain and hence organ functions. Regeneration of tissues can functions, such as cell adhesion, cell mobility and cell be achieved by the combination of living cells, which will differentiation. provide biological functionality, and materials, which act Nanomaterials used in biomedical applications include as scaffolds to support cell proliferation. Mammalian nanoparticles for molecules delivery (drugs, growth fac- cells behave in vivo in response to the biological signals tors, DNA), nanofibres for tissue scaffolds, surface modifi- they receive from the surrounding environment, which is cations of implantable materials or nanodevices, such as structured by nanometre-scaled components. Therefore, biosensors. The combination of these elements within materials used in repairing the human body have to tissue engineering (TE) is an excellent example of the reproduce the correct signals that guide the cells great potential of nanotechnology applied to regenerative towards a desirable behaviour. Nanotechnology is not medicine. The ideal goal of regenerative medicine is the in only an excellent tool to produce material structures that vivo regeneration or, alternatively, the in vitro generation mimic the biological ones but also holds the promise of of a complex functional organ consisting of a scaffold made providing efficient delivery systems.
  • Serial Interval and Incubation Period of COVID-19

    Serial Interval and Incubation Period of COVID-19

    Alene et al. BMC Infectious Diseases (2021) 21:257 https://doi.org/10.1186/s12879-021-05950-x RESEARCH ARTICLE Open Access Serial interval and incubation period of COVID-19: a systematic review and meta- analysis Muluneh Alene1, Leltework Yismaw1, Moges Agazhe Assemie1, Daniel Bekele Ketema1, Wodaje Gietaneh1 and Tilahun Yemanu Birhan2* Abstract Background: Understanding the epidemiological parameters that determine the transmission dynamics of COVID- 19 is essential for public health intervention. Globally, a number of studies were conducted to estimate the average serial interval and incubation period of COVID-19. Combining findings of existing studies that estimate the average serial interval and incubation period of COVID-19 significantly improves the quality of evidence. Hence, this study aimed to determine the overall average serial interval and incubation period of COVID-19. Methods: We followed the PRISMA checklist to present this study. A comprehensive search strategy was carried out from international electronic databases (Google Scholar, PubMed, Science Direct, Web of Science, CINAHL, and Cochrane Library) by two experienced reviewers (MAA and DBK) authors between the 1st of June and the 31st of July 2020. All observational studies either reporting the serial interval or incubation period in persons diagnosed with COVID-19 were included in this study. Heterogeneity across studies was assessed using the I2 and Higgins test. The NOS adapted for cross-sectional studies was used to evaluate the quality of studies. A random effect Meta- analysis was employed to determine the pooled estimate with 95% (CI). Microsoft Excel was used for data extraction and R software was used for analysis.
  • A Systematic Review of COVID-19 Epidemiology Based on Current Evidence

    A Systematic Review of COVID-19 Epidemiology Based on Current Evidence

    Journal of Clinical Medicine Review A Systematic Review of COVID-19 Epidemiology Based on Current Evidence Minah Park, Alex R. Cook *, Jue Tao Lim , Yinxiaohe Sun and Borame L. Dickens Saw Swee Hock School of Public Health, National Health Systems, National University of Singapore, Singapore 117549, Singapore; [email protected] (M.P.); [email protected] (J.T.L.); [email protected] (Y.S.); [email protected] (B.L.D.) * Correspondence: [email protected]; Tel.: +65-8569-9949 Received: 18 March 2020; Accepted: 27 March 2020; Published: 31 March 2020 Abstract: As the novel coronavirus (SARS-CoV-2) continues to spread rapidly across the globe, we aimed to identify and summarize the existing evidence on epidemiological characteristics of SARS-CoV-2 and the effectiveness of control measures to inform policymakers and leaders in formulating management guidelines, and to provide directions for future research. We conducted a systematic review of the published literature and preprints on the coronavirus disease (COVID-19) outbreak following predefined eligibility criteria. Of 317 research articles generated from our initial search on PubMed and preprint archives on 21 February 2020, 41 met our inclusion criteria and were included in the review. Current evidence suggests that it takes about 3-7 days for the epidemic to double in size. Of 21 estimates for the basic reproduction number ranging from 1.9 to 6.5, 13 were between 2.0 and 3.0. The incubation period was estimated to be 4-6 days, whereas the serial interval was estimated to be 4-8 days. Though the true case fatality risk is yet unknown, current model-based estimates ranged from 0.3% to 1.4% for outside China.
  • Cancer Nanomedicine: from Targeted Delivery to Combination Therapy

    Cancer Nanomedicine: from Targeted Delivery to Combination Therapy

    Review Cancer nanomedicine: from targeted delivery to combination therapy 1,2,3 1 1 1,2 Xiaoyang Xu , William Ho , Xueqing Zhang , Nicolas Bertrand , and 1 Omid Farokhzad 1 Laboratory of Nanomedicine and Biomaterials, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA 2 The David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA 3 Department of Chemical, Biological and Pharmaceutical Engineering, New Jersey Institute of Technology, Newark, NJ 07102, USA The advent of nanomedicine marks an unparalleled op- advantages of NPs have brought widespread attention to portunity to advance the treatment of various diseases, the field of nanomedicine, including their large ratio of including cancer. The unique properties of nanoparticles volume to surface area, modifiable external shell, biode- (NPs), such as large surface-to-volume ratio, small size, gradability, and low cytotoxicity [4]. Furthermore, nano- the ability to encapsulate various drugs, and tunable medicine brings us dramatically closer to realizing the full surface chemistry, give them many advantages over their promise of personalized medicine [5]. bulk counterparts. This includes multivalent surface mod- Engineered therapeutic NPs offer numerous clinical ification with targeting ligands, efficient navigation of the advantages. Surface modification with polyethylene glycol complex in vivo environment, increased intracellular traf- (PEG) protects NPs from clearance from the blood by the ficking, and sustained release of drug payload. These mononuclear phagocytic system (MPS), markedly increasing advantages make NPs a mode of treatment potentially both circulation times and drug uptake by target cells superior to conventional cancer therapies. This review [2,6].